Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
18 participants
OBSERVATIONAL
2016-05-31
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Leukocyte-rich PRP or Leukocyte-free PRP vs Placebo in the Treatment of Epicondylitis
NCT06040203
PEAK Platelet Rich Plasma Injection Treatment for Chronic Lateral Epicondylosis
NCT03072381
How Does Platelet Dose Impact Clinical Outcomes After PRP Treatment?
NCT05330689
Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial
NCT02923700
Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip
NCT02183896
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Leukocyte- and Platelet-Rich Plasma (L-PRP)
The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female of ≥ 18 years of age
3. Confirmed diagnosis of unilateral chronic LE
4. Duration of chronic LE symptoms ≥ 3 months
5. Failed at least one previous LE treatment (e.g. wait and see, physiotherapy, analgesics, NSAIDs, anti-inflammatory steroid injection and bracing, etc.).
Exclusion Criteria
7. No active leukemia or metastatic malignant cells
8. No current chemotherapy treatments
9. No pregnancy
10. No lactation
11. No infected tendons, skin infection or skin disease in the area of the injection site.
12. Participating in another drug or device study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zimmer Biomet
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Watts, MD
Role: PRINCIPAL_INVESTIGATOR
Wrightington Hospital, Wigan, United Kingdom
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wrightington Hospital
Appley Bridge, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BBIO.CR.LPRP.PMD.001.15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.